Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Glesatinib |
Synonyms | |
Therapy Description |
Glesatinib (MGCD265) inhibits several tyrosine kinases including MET (type II inhibitor), MST1R (RON), and AXL, as well as VEGFR1-3, and TIE2, which may result in decreased tumor growth (PMID: 25806189, PMID: 26555154, PMID: 32306194). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Glesatinib | MGCD-265|MGCD 265 | AXL Inhibitor 30 MET Inhibitor 59 RON Inhibitor 11 VEGFR Inhibitor (Pan) 36 | Glesatinib (MGCD265) inhibits several tyrosine kinases including MET (type II inhibitor), MST1R (RON), and AXL, as well as VEGFR1-3, and TIE2, which may result in decreased tumor growth (PMID: 25806189, PMID: 26555154, PMID: 32306194). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
AXL amp | lung non-small cell carcinoma | predicted - sensitive | Glesatinib | Phase I | Actionable | In a Phase I trial, a patient with non-small cell lung carcinoma harboring AXL amplification was sensitive to treatment with Glesatinib (MGCD265), demonstrating a 50% decrease in lesion size (PMID: 26555154). | 26555154 |
AXL amp | lung non-small cell carcinoma | predicted - sensitive | Glesatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Glesatinib (MGCD265) treatment resulted in partial responses (PR) as the best response in 9 of 49 evaluable patients with advanced solid tumors harboring MET or AXL alterations, including a PR lasting 3.5 years in a patient with AXL-amplified (CN 13) non-small cell lung cancer (PMID: 36459255; NCT00697632). | 36459255 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02544633 | Phase II | Glesatinib | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | Completed | USA | ITA | GBR | CAN | AUS | 4 |
NCT00697632 | Phase I | Glesatinib | Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies | Completed | USA | CAN | 1 |